GENELUX CORP (GNLX) Stock News

NASDAQ:GNLX - Nasdaq - US36870H1032 - Common Stock - Currency: USD

3.36 -0.07 (-2.04%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

GNLX Latest News, Press Relases and Analysis

All

Press Releases

13 days ago - By: Genelux Corporation

Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates

13 days ago - By: Genelux Corporation

Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates

a month ago - By: Benzinga - Mentions: RFL CYCC CRL ONMD ...

12 Health Care Stocks Moving In Monday's After-Market Session

a month ago - By: Genelux Corporation

Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

a month ago - By: Genelux Corporation

Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

a year ago - By: BusinessInsider

News Image

GNLX Stock Earnings: Genelux Beats EPS for Q2 2024

3 months ago - By: Zacks Investment Research

Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know

3 months ago - By: Benzinga - Mentions: DCTH QDEL EBS CYRX ...

12 Health Care Stocks Moving In Thursday's Intraday Session

4 months ago - By: Genelux Corporation

Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates

4 months ago - By: Genelux Corporation

Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates

4 months ago - By: Genelux Corporation

Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference

a year ago - By: InvestorPlace

GNLX Stock Earnings: Genelux Beats EPS for Q2 2024

4 months ago - By: Zacks Investment Research

Is EUROFINS SCIENT (ERFSF) Outperforming Other Medical Stocks This Year?

5 months ago - By: Genelux Corporation

Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

5 months ago - By: Genelux Corporation

Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

5 months ago - By: Genelux Corporation

Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock

5 months ago - By: Genelux Corporation

Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock

5 months ago - By: Genelux Corporation

Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer

5 months ago - By: Genelux Corporation

Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease

5 months ago - By: Genelux Corporation

Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease

5 months ago - By: Genelux Corporation

Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer

7 months ago - By: Genelux Corporation

Genelux Corporation Announces New Chief Financial Officer

7 months ago - By: Genelux Corporation

Genelux Corporation Announces New Chief Financial Officer

8 months ago - By: Genelux Corporation

Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright

8 months ago - By: Genelux Corporation

Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright

9 months ago - By: Genelux Corporation

Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates

9 months ago - By: Genelux Corporation

Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates

10 months ago - By: Genelux Corporation

Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference

10 months ago - By: Genelux Corporation

Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference

10 months ago - By: Genelux Corporation

Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer

10 months ago - By: Genelux Corporation

Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer

11 months ago - By: Genelux Corporation

Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit

11 months ago - By: Genelux Corporation

Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit

a year ago - By: Genelux Corporation

Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

a year ago - By: Genelux Corporation

Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

a year ago - By: Genelux Corporation

Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates